These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37357936)
1. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer. Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936 [TBL] [Abstract][Full Text] [Related]
2. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Baine MK; Febres-Aldana CA; Chang JC; Jungbluth AA; Sethi S; Antonescu CR; Travis WD; Hsieh MS; Roh MS; Homer RJ; Ladanyi M; Egger JV; Lai WV; Rudin CM; Rekhtman N J Thorac Oncol; 2022 Sep; 17(9):1109-1121. PubMed ID: 35760287 [TBL] [Abstract][Full Text] [Related]
3. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor. Kim G; Kim M; Nam EJ; Lee JY; Park E Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832 [TBL] [Abstract][Full Text] [Related]
4. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038 [TBL] [Abstract][Full Text] [Related]
5. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388 [TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma. Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891 [TBL] [Abstract][Full Text] [Related]
7. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap. Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277 [TBL] [Abstract][Full Text] [Related]
8. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888 [TBL] [Abstract][Full Text] [Related]
9. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin. Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975 [TBL] [Abstract][Full Text] [Related]
11. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573 [TBL] [Abstract][Full Text] [Related]
12. POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity. Szczepanski AP; Tsuboyama N; Watanabe J; Hashizume R; Zhao Z; Wang L Sci Adv; 2022 Oct; 8(40):eabq2403. PubMed ID: 36197978 [TBL] [Abstract][Full Text] [Related]
13. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. Simbolo M; Centonze G; Ali G; Garzone G; Taormina S; Sabella G; Ciaparrone C; Mafficini A; Grillo F; Mangogna A; Volante M; Mastracci L; Fontanini G; Pilotto S; Bria E; Infante M; Capella C; Rolli L; Pastorino U; Milella M; Milione M; Scarpa A ESMO Open; 2022 Feb; 7(1):100308. PubMed ID: 34952268 [TBL] [Abstract][Full Text] [Related]
14. Expression and Clinicopathological Significance of SOX11 in Small-Cell Lung Cancer. Xinli W; Lixiao W; Baoqi D; Hu H; Qiang Z Biomed Res Int; 2022; 2022():1707914. PubMed ID: 35402616 [TBL] [Abstract][Full Text] [Related]
15. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures. Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352 [TBL] [Abstract][Full Text] [Related]
16. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680 [TBL] [Abstract][Full Text] [Related]
17. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC? Kawai H; Matsuoka R; Ito T; Matsubara D Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340 [TBL] [Abstract][Full Text] [Related]
18. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma. Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667 [TBL] [Abstract][Full Text] [Related]
19. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3. Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220 [TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma. Zhu Y; Li S; Wang H; Ren W; Chi K; Wu J; Mao L; Huang X; Zhuo M; Lin D J Clin Pathol; 2023 Sep; ():. PubMed ID: 37775262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]